Ghrelin O-acyltransferase inhibitors

This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syn...

Full description

Saved in:
Bibliographic Details
Main Authors Eidam, Hilary Schenck, Cheung, Mui, Joshi, Hemant, Su, Dai-Shi, Bandyopadhyay, Anish
Format Patent
LanguageEnglish
Published 26.04.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g., alcohol, smoking, overeating, or use of illicit drugs))), as well as disorders related to or complications of metabolic or psychiatric disorders (e.g., cardiovascular diseases (e.g., diabetic heart disease (e.g., diabetic cardiomyopathy), heart failure, or hypertension), ischemia (e.g., myocardial ischemia, cerebral ischemia, ischemic stroke), or BMI-related cancers (e.g., pancreatic cancer, gallbladder cancer, esophageal cancer, colorectal cancer, breast cancer etc.).
AbstractList This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g., alcohol, smoking, overeating, or use of illicit drugs))), as well as disorders related to or complications of metabolic or psychiatric disorders (e.g., cardiovascular diseases (e.g., diabetic heart disease (e.g., diabetic cardiomyopathy), heart failure, or hypertension), ischemia (e.g., myocardial ischemia, cerebral ischemia, ischemic stroke), or BMI-related cancers (e.g., pancreatic cancer, gallbladder cancer, esophageal cancer, colorectal cancer, breast cancer etc.).
Author Bandyopadhyay, Anish
Su, Dai-Shi
Cheung, Mui
Eidam, Hilary Schenck
Joshi, Hemant
Author_xml – fullname: Eidam, Hilary Schenck
– fullname: Cheung, Mui
– fullname: Joshi, Hemant
– fullname: Su, Dai-Shi
– fullname: Bandyopadhyay, Anish
BookMark eNrjYmDJy89L5WRQcc8oSs3JzFPw101MrswpKUrMK05LLUosTlXIzMvITMosyS8q5mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8aHBhobGhkbmBpZORsbEqAEADv0o9A
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US11312709B2
GroupedDBID EVB
ID FETCH-epo_espacenet_US11312709B23
IEDL.DBID EVB
IngestDate Fri Jul 19 15:14:32 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US11312709B23
Notes Application Number: US201916967262
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220426&DB=EPODOC&CC=US&NR=11312709B2
ParticipantIDs epo_espacenet_US11312709B2
PublicationCentury 2000
PublicationDate 20220426
PublicationDateYYYYMMDD 2022-04-26
PublicationDate_xml – month: 04
  year: 2022
  text: 20220426
  day: 26
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies Glaxosmithkline Intellectual Property Development Limited
RelatedCompanies_xml – name: Glaxosmithkline Intellectual Property Development Limited
Score 3.4022784
Snippet This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title Ghrelin O-acyltransferase inhibitors
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220426&DB=EPODOC&locale=&CC=US&NR=11312709B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1NS8Mw9DGmqDedis4PKozeil2atc2hCP1yCFuHW2W3YdIUK1LHVhH_vS-lc170FhJ4SR687y-AnjS5LYXyaziUGzTPmMEyhxnUFWxABBFOpvyQo7E9TOnDfDBvweumFqbuE_pZN0dEihJI71XNr5dbJ1ZY51aub3mBW-938cwL9cY6JkSZBHroe9EkCZNADwIvnerjR6_ft1SMlfnIrneUGq367EdPvqpKWf4WKfEh7E4QWlkdQUuWHdgPNpPXOrA3agLeuGxob30MvXtEOyqFWmI8i6-3qtY45QqlkFaULwUv1NycE7iJo1kwNPC6xc_fFul0-zLrFNpo88sz0HLCuMkk59SUlNPcpdQhUkjKMsJc1zqH7t9wuv8dXsCBwpMKiBD7EtrV6kNeoVyt-HWNkG8zUHw9
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1NS8Mw9DGmOG86FZ1fFUZvxS3N2uZQhLarVdd2uFZ2GyZNsSJ1bBXx35uUzXnRW0jgJXnwvr8AurxHDc6kX8PEVMN5RjSSmUTDFiMDxBAzM-mHDCMjSPH9dDBtwOu6FqbuE_pZN0cUFMUEvVc1v55vnFhenVu5vKaF2Hq_8RPbU1fWMULSJFA9xx6OYy92Vde104kaPdr9vi5jrMQR7HrLlN15per05MiqlPlvkeLvwfZYQCurfWjwsg0tdz15rQ074SrgLZYr2lseQPdWoF0ohUqsPbOvt6rWOPlCSCGlKF8KWsi5OYdw5Q8TN9DEdbOfv83SyeZl-hE0hc3Pj0HJEaE9winFPY4pzi2MTcQZxyRDxLL0E-j8Dafz3-EltIIkHM1Gd9HDKexKnMngCDLOoFktPvi5kLEVvaiR8w0qtn8q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Ghrelin+O-acyltransferase+inhibitors&rft.inventor=Eidam%2C+Hilary+Schenck&rft.inventor=Cheung%2C+Mui&rft.inventor=Joshi%2C+Hemant&rft.inventor=Su%2C+Dai-Shi&rft.inventor=Bandyopadhyay%2C+Anish&rft.date=2022-04-26&rft.externalDBID=B2&rft.externalDocID=US11312709B2